Female worker are "half the sky" ofthe enterprise development, care for their health is always the concern of BoaiNKY Pharmaceuticals Ltd. In the first half of 2016, in addition to the basicphysical examination project for the female workers, specifically on the"International Women's Day" the company also gave them a warm andcaring gift -- free cervical cancer screening, which was warmly welcomed andappreciated.During 8th-10th March, there are more than130 female workers as well as the female relatives of the male workers beingtaken samples in the Second People's Hospital of Boai County. The company sent thesamples to Wuhan HEER Medical Science and Technology Development Co., Ltd. Withthe automatic cell tumor screening system, through accurate DNA ploidyquantitative analysis technique, the screening of cervical cancer andprecancerous lesions was performed.Wuhan HEER as a wholly owned subsidiary ofBoai NKY, is dedicated to the research and development of cutting-edge medicaltechnology products, as well as the relative production, sales and service. The"SPICM-DNA automatic cell tumor screening system" is developed by doctorsstudied abroad in the United States, the system combines domestic and foreignadvanced technology, which fills the domestic blank of the precancerousscreening of cervical cancer. The characteristics of the system: advanced,fast, accurate and efficient. ?The systemalso fully demonstrates the advantage of exfoliated cells: simplicity, lowcost, no damage, easy to be accepted by the patients. The systems also overcomesthe disadvantage such as poor quality, lack of cells to be observed, low positiverate of diagnosis, which lowers the risk of miss rate of the precancerousscreening of cervical cancer, and makes the large-scale cancer census to becomea reality.After the strict screening by " SPICM-DNAautomatic cell tumor screening system ", the positive results were 3, and thepositive rate was 2.3%. The screening results were timely feed backed to thepersons and the hospital, and further examination and biopsy were performed. Oneof them has been diagnosed as early-stage cervical cancer, and timely treatmentwas applied. The patient has been cured in early April and left hospital. It isjust because of the early discovery, the patient got timely treatment, which isvery short and relatively lower costly. With early diagnosis and earlytreatment, the health of the female can be well kept.The above screening results are incompliance with the current positive rate of 2.74% big data from Wuhan HEER in thescreening of mass samples of women in China, which once again proves thespecificity, sensitivity and reproducibility of the system. By early screeningand diagnosis of DNA cells, we can find the early-stage cervical cancer or relateddiseases, so that we can block the development of cancer cells before theproliferation of cancer cells, and timely and effective cure the patients. The screeningwork as mentioned above is Boai NKY's first deliberate try & effort to pushthe popularity of precancerous screening of cervical cancer. It showed verygood effect, and received warm welcome and appreciation by the workers.In the future, Boai NKY will continue to takeadvantage of its technology of genetic testing and precancerous screening, to committo promote the new health screening detection technology within the company aswell as in the society. To contribute to protect the health of employees of thecompany and all the female, as well as to promote the advanced medicaltechnology to China.

Tianjin, PR CHINA (September 15,2016) - BOAI NKY, the first Polyvinylpyrollidone (PVP) manufacturer in China and a significant manufacturer of methyl vinyl ether/maleic anhydride copolymers (PVM/MA), announces a major expansion to its Technical Support Labs. These enhanced facilities will provide our customers with outstanding support in helping them optimize their formulations in the Personal Care, Pharmaceutical and Performance Chemical markets for our range of PVP and PVM/MA polymer families.In addition, these enhanced Technical Support Labs will support BOAI NKY’s goal to broaden the application base of its OraRez® range of PVM/MA products. These products currently enjoy strengthening positions in the Oral Care market due to their excellent mucosal adhesive properties. To further build the OraRez® platform, BOAI NKY continues to develop new applications around their outstanding bioadhesive functionality, with special focus in the areas of skin protection and repair. Customers who are interested in making use of this expanded facility or discussing any of our products should contact Dr. Herb Ulmer as above or visit us at Stand 4H73, CPhI, Barcelona,October 4-6, 2016.ABOUT BOAI NKY. BOAI NKY Pharmaceuticals Ltd. (NKY stock code: 300109) was the first PVP manufacturer in China and has been manufacturing PVP’s for nearly 30 years. The Company opened a new “state of the art” manufacturing facility in Henan Province, PR China in 2013, making it the production center for our PVP and PVM/MA polymer families.All pharmaceutical, cosmetic, food and oral care polymers are manufactured under strict cGMP guidelines. With established R&D and Technical Centers, NKY is committed to the development of new products and technologies to bring new solutions and value to our customers.The Company operates through owned subsidiaries in Asia and Europe and with a network of specialist distributors. We serve customers in more than 60 countries worldwide.

Tianjin Boai NKY International Ltd., will be moving to a new office building next week, i.e. from 17th April 2017 we will be in the new office:

Invited by the NKY medical group, the chief executive of Swedish NeoDynamics , Anna Eriksrud visit Beijing on 18~21th September. NeoDynamics is a medical technology company headquartered in Sweden, which is committed to research and develop tumor diagnosis equipment. NeoDynamics has now developed NeoNavia breast biopsy system, and in June 2016 acquired the European Union CE certification. From July 2016, NKY become the biggest shareholder in the NeoDynamics.This is the first time two sides communication in China after NKY become NeoDynamics shareholder, accompanied by Ms. Eriksrud to China, and on behalf of the NKY is professor?xiao-jun Xu, Xu teaches physiology and pharmacology in Karolinska instituteMs. Eriksrud first introduced the clinical results in Europe of NeoNavia in nearly a year to NKY: Till to September 2017, NeoNavia system has eight hospitals in clinical trials in Europe, biopsy sampling for breast cancer patients, accumulative total of around 100 cases, the success rate of about 95%. In addition, a small number of axillary lymph node biopsy is performed, with a success rate of up to 100%. The European doctors involved in clinical trials have given the NeoNavia system a high rating.Just in three days, Ms. Eriksrud respectively visited Beijing mammary gland disease prevention and control of society, the Chinese people's liberation army 307 hospital and scientific Chinese medicine tumor hospital. And has carried on the exchange communication respectively with Huang Yan team of 307 hospital surgical oncology and director wang team of mammary gland tumor hospital.Two experts understand the working principle of NeoNavia system in detail, compare the difference with the existing biopsy device and published their opinion, the two experts have expressed interest in cooperation for clinical testing in China.At the end of the trip, Ms. Eriksrud has strong confidence in the development prospects of NeoNavia in Chinese market. She believes that the rapid development of China's economy and the importance of early diagnosis and treatment of cancer will have a very positive impact on the market of medical products. NKY has excellent brand influence and market appeal in China, which can help to achieve the NeoDynamics market goal in China, and make a number of high technology of NeoDynamics benefit cancer patients.